Year: 2020
Type: editorial
Abstract: Morris et al (page 2206) newly report that memory CD8 + T cells, the main mediators of alloimmune response, express the checkpoint molecule FcγRIIB, which controls their activation and survival and therefore represents a potential therapeutic target for selective antirejection therapies.
DOI: 10.1111/ajt.15854
Author: Paolo Cravedi
Institution: Icahn School of Medicine at Mount Sinai
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,300
OpenAlex ID: W3011970024